Sumitomo Corporation (Sumitomo Shoji Kaisha,Ltd.) (8053) · RiskMitigated
Emergence of impairment risk due to intensifying competition in the U.S. pharmaceutical business
First written in FY2022. 1 of 2 entries say "Materialised", first in FY2022. Latest entry: FY2025-H1.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
米国製薬事業の競争激化による減損損失A theme 1 companies write about · 1 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2025-H1MitigatedAnnual report
「Asset recycling: Sale of policy-held shares, proceeds recovered from the sale of the U.S. pharmaceuticals business, and other measures」
The company disclosed the recovery of funds following the sale of the US pharmaceutical business, indicating a reduction in its investment exposure to the business, which had previously incurred impairment losses amid intensifying competition and other factors. - FY2022MaterialisedAnnual report
「At Upsher-Smith Laboratories, LLC, the US pharmaceutical operating company, the company reviewed its future business plans in light of changes in the operating environment, including the entry of competitors into the markets for its products. As a result, an impairment loss of ¥15,125 million was recorded on investments held by the group in the Resources and Chemicals segment.」
Following a review of the business plan due to the entry of competitors and other factors, an impairment loss of ¥15.125 billion was incurred in the US pharmaceutical business.